How do you approach patients with AL amyloidosis with t(11;14) who have not achieved a hematologic complete response to induction therapy with 6 cycles of Dara-CyBorD?   

Achieving an early hem deep response (at least VGPR or better) is crucial for organ response and has demonstrated OS benefit.I would favor changing treatment even by cycle 4 if the hematologic response is <PR. Early switch in such situations led to improved EFS and better chances for an organ res...

Excellent question, and always a frustrating scenario because of how excitedly we discuss the rise of daratumumab with our newly diagnosed patients when they're diagnosed and feeling terrible.I assume the patient here doesn't have any myeloma-defining events, which is a story for another day (and pr...